98%
921
2 minutes
20
Background: The hepatic metabolism of patients with hepatocellular carcinoma and cirrhosis (HCCC) may differ from that of patients with hepatocellular carcinoma (HCC) without cirrhosis, limiting the clinical individualized dosing regimens for these patients. Microsomal protein per gram of liver (MPPGL) is an important scaling factor for physiologically based pharmacokinetic models, but data in patients with HCCC are limited. The study aims to determine the content of MPPGL in patients with HCCC and to guide individualized clinical dosing of patients with HCCC using drug metabolism data.
Methods: The microsomal protein content was determined in liver samples of patients with HCCC (n=48) and in normal liver samples (n=68). The activity of 10 cytochrome P450 (CYP) isoforms at the microsomal protein level (CL) was determined. According to the value of MPPGL and CL, the activity of CYPs in the liver tissue clearance (CL) and predicted hepatic clearance (CL) were extrapolated.
Results: The median value of MPPGL was significantly lower in patients with HCCC (28.35 mg/g) than in the controls (37.65 mg/g) (P=0.008). In patients with HCCC as compared to controls, the CL of CYP1A2, CYP2C8, and CYP2C19 was significantly decreased while that of CYP2D6 and CYP2E1 was significantly increased; meanwhile, the CL of CYP2A6, CYP2B6, CYP2C9, and CYP3A4/5 was not significantly changed. The changes in CL were not consistent with those in CL among patients with HCCC. The median spearman rank correlation coefficient was 0.7880±0.079 between CL and CL and was 0.9868±0.022 between CL and CL for the 10 CYPs (P<0.001).
Conclusions: In patients with HCCC, MPPGL content was significantly reduced, and a variable change in the activity of 10 CYP was observed in microsomes. When taking individual MPPGL into account, CL is better suited than CL to represent the metabolism of CYPs, with the strongest correlation being observed between CL and CL. This finding holds potential value for guiding clinical management of drugs in patients with HCCC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921222 | PMC |
http://dx.doi.org/10.21037/jgo-2024-963 | DOI Listing |
PLoS One
August 2025
The Department of Pancreatic Surgery, General Surgery Department, Nanyang City Center Hospital, Nanyang, Henan, China.
The aim of this study was to investigate how the cholangiocarcinoma cell lines RBE and HCCC-9810 responded to NCOA4 downregulation in terms of proliferation, migration and invasive.First,we analyzed the differential expression and survival prognosis of the NCOA4 gene using a bioinformatic approach,as well as validation using clinical samples.Next,cholangiocarcinoma cells were cultured and the NCOA4 gene was down-regulated with siRNA,and then NCOA4 and GPX4 expression was detected using qPCR and Western blot.
View Article and Find Full Text PDFBraz J Otorhinolaryngol
July 2025
Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, China. Electronic address:
Objective: To study clinicopathological features and differential diagnosis of hyalinizing clear cell carcinoma in the head and neck.
Methods: A retrospective analysis was performed patients with hyalinizing clear cell carcinoma in the head and neck, who underwent surgical resection in Beijing Tongren Hospital affiliated to Capital Medical University from January 2014 to May 2024. The clinical features of HCCC were analyzed by computed tomography and magnetic resonance imaging.
Cureus
March 2025
Otolaryngology - Head and Neck Surgery, Kochi Medical School Hospital, Kochi University, Nankoku, JPN.
Hyalinizing clear cell carcinoma (HCCC) is a rare low-grade malignant tumor composed of clear cytoplasmic cells. It mainly arises from the minor salivary glands of the oral cavity and oropharynx of the head and neck region. As a relatively slow-growing tumor, the main symptom of HCCC is indolent discomfort associated with enlargement and little local pain.
View Article and Find Full Text PDFJ Gastrointest Oncol
February 2025
Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, China.
Background: The hepatic metabolism of patients with hepatocellular carcinoma and cirrhosis (HCCC) may differ from that of patients with hepatocellular carcinoma (HCC) without cirrhosis, limiting the clinical individualized dosing regimens for these patients. Microsomal protein per gram of liver (MPPGL) is an important scaling factor for physiologically based pharmacokinetic models, but data in patients with HCCC are limited. The study aims to determine the content of MPPGL in patients with HCCC and to guide individualized clinical dosing of patients with HCCC using drug metabolism data.
View Article and Find Full Text PDFBiochim Biophys Acta Mol Basis Dis
April 2025
Department of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China. Electronic address:
Intrahepatic cholangiocarcinoma (ICC), an aggressive liver cancer, lacks simple and accurate clinical tests, which poses challenges to postoperative diagnosis and treatment. Recent studies have indicated that platelet levels might be relevant to the postoperative prognosis of ICC. However, their prognostic significance in ICC remains unclarified.
View Article and Find Full Text PDF